Large Japanese Sponsor Partners with Bioclinica for End-to-End Pharmacovigilance Case Processing Introduction Monitoring of adverse event cases is an important step during the post marketi ng phase (Phase IV) of an approved drug. When a potenti al adverse event occurs, and is reported to the physician, regulatory agency or sponsor by the pati ent, it must be reviewed, aggregated with other similar cases in the databases or literature and repo

Join for free to read